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ABSTRACT
Apergillus is a ubiquitious mould that can cause a wide variety of clinical syndromes ranging from mere
colonisation to fulminant invasive disease. Invasive aspergillosis (IA) is the most severe presentation of
aspergillosis. The lung is usually the portal of entry, from which the pathogen may disseminate to
almost any organ, often the brain and skin. The diagnosis remains a signiﬁcant challenge. It is usually
based on a combination of compatible clinical ﬁndings in a patient with risk-factors and isolation of the
microorganism, radiological data, serological detection of antibodies or antigens, or histopathological
evidence of invasion. Chest radiographic ﬁndings in patients with pulmonary Aspergillus may initially
be normal in up to 10% of cases. Computed tomography scanning is probably the most useful imaging
technique for the diagnosis of IA, since it may reveal lung lesions up to 5 days earlier than would
radiograph techniques simply. Currently available laboratory diagnostic methods include several
techniques: histopathological evidence of invasion; isolation of the microorganism and direct
microscopy from clinical samples and non-invasive procedures (serological detection of antigens or
nucleic material of Aspergillus; detection of antibodies). The histological diagnosis of IA requires the
presence of invasion by fungus of the Aspergillus species. The truth is that, if no other variables are
considered, the positive predictive value is very low, and most of the isolates of A. fumigatus do not
represent proven or probable infection. Several molecules could be used as markers of infection, but two
of them are of special interest: Aspergillus galactomannan (GM) and (1 ﬁ 3)-b-glucan (BG). GM has a
high speciﬁcity (above 85%) and a reported sensitivity that varies widely (between 30% and 100%). BG,
a main cell wall polysaccharide component of Aspergillus, can be colourimetrically detected and is useful
in diagnosis, with a sensitivity ranging from 50% to 87.5%. A speciﬁc Aspergillus PCR assay has also
been used in the diagnosis of IA and has shown very good results, with a sensitivity and speciﬁcity of
100% and 89%, respectively.
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INTRODUCTION
Aspergillus is airborne in all environments, both
inside and outside the hospital. Only a few
species cause human illness, and the immunolo-
gical status of the individual and the condition of
the lung determine the pattern of disease.
In all hosts, the most common species of
Aspergillus causing disease is Aspergillus fumiga-
tus. Far less common are infections caused by
Aspergillus ﬂavus, Aspergillus niger and Aspergillus
terreus. Mortality associated with invasive asper-
gillosis (IA) is nearly 100% if the disease is not
treated [1]. The attributable mortality of IA varies
depending on the type of infectious episode: 60%
in global terms, 40% for pulmonary disease, 90%
for disseminated disease and practically 100% for
disseminated disease with central nervous system
(CNS) involvement [2].
In this review, the epidemiology of Aspergillus
infection and the therapeutic and prophylactic
approach to this infection are examined by con-
centrating on the clinical and diagnostic aspects of
the disease. We summarise the status of current
knowledge and recommend three excellent
reviews that may be of interest [3–5].
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Clinical manifestations of Aspergillus infection
Aspergillus can cause a wide variety of clinical
syndromes, ranging from mere colonisation to
fulminant invasive disease. As clinicians become
more aware of the classic foms of the disease (i.e.,
IA in neutropenic patients) and effective prevent-
ive measures are established, the face of the
disease is changing. In institutions such as ours,
IA in chronic obstructive pulmonary disease
patients now outnumbers cases in ‘classic
patients’ [6]. Table 1 shows the underlying con-
ditions of the cases of IA diagnosed in our
institution over the last few years.
Furthermore, recently characterised ‘border
presentations’ such as semi-invasive or chronic
forms demonstrate that there is a certain overlap
between entities. Progression from a less aggres-
sive to a more aggressive form is not common [7].
Speciﬁc risk-factors and the host immune system
determine which form of aspergillosis develops;
for example, acutely invasive aspergillosis is
usually found in deeply immunosuppressed
patients.
Allergic bronchopulmonary aspergillosis
Allergic bronchopulmonary aspergillosis (ABPA),
the least invasive disease caused by Aspergillus, is
an infrequent chronic disease caused by hyper-
sensitivity to the fungus Aspergillus fumigatus,
which complicates the evolution of disease in 1–
2% of patients with asthma and in 2–15% with
cystic ﬁbrosis [8]. More uncommon underlying
conditions are hyper-immunoglobulin E syn-
drome or chronic granulomatous disease. ABPA
must be recognised early to avoid progression to
bronchiectasis and parenchymal damage.
ABPA typically presents with periods of
exacerbation and others of remission. Airway
colonisation by Aspergillus exacerbates underlying
airway injury, leading to chronic inﬂammation
and ﬁbrosis with destruction of bronchial ele-
ments, bronchiectasis and scarring. The patients
most affected are atopic individuals in their third
to ﬁfth decade, with a history of allergy and
asthma that is difﬁcult to control.
As with other diseases, e.g., rheumatic fever,
no single diagnostic ﬁnding is sufﬁcient, so a set
of clinical, laboratory and radiographic criteria
is needed (Table 2). Six clinical criteria make the
diagnosis probable: (1) asthma; (2) peripheral
eosinophilia; (3) immediate skin test reactivity to
Aspergillus (IgE); (4) precipitating antibodies to
Aspergillus (IgG); (5) elevated serum IgE; and (6)
pulmonary inﬁltrates, which may be transient or
ﬁxed. The ﬁrst ﬁve are required criteria for
ABPA in patients with asthma.
Other possible clinical criteria include: a spu-
tum culture positive for Aspergillus, or detection
of compatible hyphae on smears, mucous plugs
with degenerated eosinophils (Charcot–Leyden
crystals) in sputum, and inﬁltrates on chest X-rays
suggesting bronchial inﬂammation. In patients
with cystic ﬁbrosis, eosinophilia is not a useful
diagnostic tool [9]. Lung biopsy is not usually
required for the diagnosis. If it is performed,
allergic mucin and fungal hyphae indicate the
presence of ABPA.
Therapy is aimed at reducing inﬂammation and
immunological activity. Management includes the
Table 1. Underlying conditions of 260 patients with
Aspergillus fumigatus recovered in culture (406 isolates)
and 31 patients with invasive aspergillosis detected in a
general hospital
Underlying
conditions
No. of
patients
No. of
isolates
Cases of
invasive
aspergillosis
Solid-organ tumour 29 39 3 (10.3%)
COPD + corticoids 100 179 10 (10%)
Leukaemia 10 18 6 (60%)
Lymphoma 6 8 1 (16.7%)
Transplant patients 17 29 2 (11.8%)
HIV 27 50 4 (15%)
Other risk factors 71 91 5 (7%)
Total 260 404 31
COPD, chronic obstructive pulmonary disease.
Fig. 1. Pulmonary aspergillosis in a transplant recipient.
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use of corticosteroids during exacerbations as
well as antifungal drugs. A recent Cochrane meta-
analysis supports the administration of itracon-
azole (200 mg for at least 16 weeks) [8].
Aspergillus has also been related to rare cases of
allergic fungal sinusitis [10–12]. Advanced aller-
gic sinusitis may be complicated by histological
evidence of tissue invasion, and the non-invasive
and invasive forms of fungal sinusitis may coexist
in the same patient.
COLONISATION AND SUPERFICIAL
ASPERGILLOSIS
Aspergilloma
When Aspergillus colonises a pre-existing lung
cavity, a fungus ball formed by masses of hyphae,
blood clot and cellular debris, called an aspergil-
loma, may appear. This typically affects apex
lesions caused by previous tuberculosis (up to
17% of such patients) or other chronic lung
diseases such as lung abscess, sarcoidosis,
emphysema, neoplasms, or pneumocystis in
AIDS.
Sometimes the patient is asymptomatic; how-
ever, most patients present with haemoptysis or
productive cough, chest pain, dyspnoea, fever,
weight loss, or clubbing. The diagnosis is estab-
lished radiologically by computed tomography
(CT) and conﬁrmed by culture or histological
identiﬁcation of Aspergillus hyphae in sputum,
bronchoalveolar lavage ﬂuid, or trans-thoracic
needle aspirates, or by serological demonstration
of Aspergillus precipitins. Most lesions are solitary
and occur in the upper lobes. Cavities average 3–
5 cm in diameter. An air crescent lies above the
fungus ball, which may move when the patient
changes position. The wall and the adjacent
pleura show variable thickening.
Therapeutic options are controversial. Approxi-
mately 10% of cases resolve spontaneously. Sur-
gery is recommended for severe haemoptysis, but
post-operative complications include broncho-
pleural ﬁstula and empyema. Instillation of var-
ious antifungal agents or iodides into the cavity
sometimes controls bleeding. An associated inva-
sive disease may occur, especially in AIDS
patients. The role of antifungal agents is not clear
when local invasion is not established. Asper-
gillomas carry a 40% 5-year survival rate [13].
Aspergillomas may also appear in the parana-
sal sinuses [14], kidney [15] and even brain tissue
[16].
Other chronic forms of pulmonary aspergillosis
Other chronic forms of pulmonary aspergillosis
that have systemic symptoms have been charac-
terised by Denning, who proposed the following
nomenclature. Chronic cavitary pulmonary asper-
gillosis (CCPA) is a form in which the cavities,
with or without fungus balls, in the lung increase
and expand; in some cases, this progresses to
extensive pulmonary ﬁbrosis, termed chronic
ﬁbrosing pulmonary aspergillosis. Pleural
involvement may occur due to direct invasion or
ﬁbrosis. Fibrosis may be limited in extension, but
also commonly involves the whole hemithorax.
The third form is chronic necrotising pulmonary
aspergillosis (CNPA), or sub-acute invasive pul-
monary aspergillosis, in which slow progression
of one single cavity may be detected over time
(months or weeks), the cavity sometimes reaching
Table 2. Criteria of allergic bronchopulmonary aspergillosis for patients with asthma or cystic ﬁbrosis
Asthmatic
patients
Asthma
Central bronchiectasis on chest tomography
Immediate cutaneous reactivity to Aspergillus species (or Aspergillus fumigatus)
Total serum IgE concentration greater than 417 IU ⁄mL (1000 ng ⁄mL)
Elevated serum IgE and ⁄ or IgG antibody to Aspergillus fumigatus
Transient inﬁltrates on chest radiograph
Serum precipitins (antibodies) against Aspergillus fumigatus
Peripheral blood eosinophilia
Cystic
ﬁbrosis
patients
Clinical deterioration not attributable to other aetiology
Immediate cutaneous reactivity to Aspergillus species or presence of IgE to Aspergillus fumigatus
Total serum IgE concentration greater than 500 IU ⁄mL (120 ng ⁄mL)
One of the following: precipitins to Aspergillus fumigatus or new or recent bronchiectasis in CT scans
or chest X-ray (mucous plugging ⁄ inﬁltrates) that do not clear after antibiotics and physiotherapy
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large dimensions. In general, expansion of a
cavity is much more rapid than in patients with
CCPA. Patients with CNPA usually have some
degree of immunosuppression (diabetes or corti-
costeroid use) [13]. CNPA and aspergilloma are
probably a continuum of the same pathological
process. Furthermore, it is likely that what has
been termed complex aspergilloma is synony-
mous with CCPA, although some patients with
CCPA do not have aspergillomas within the
cavities. Usually, there is less pleural thickening
in CCPA than in aspergilloma, but more pulmon-
ary ﬁbrosis or an enlarging cavity is seen. The
distinctions among these categories reﬂect the
dominant clinical and radiological manifestations
and their evolution over time.
Constitutional symptoms are practically always
present and include weight loss (94%), malaise
and fatigue (28%). Cough (78%), shortness of
breath (50%), haemoptysis (58%), chest pain
(17%), sputum production (11%) and fever
(11%) have also been found. The most common
clinical presentation involves chronic productive
cough, with weight loss and shortness of breath.
All patients have radiological evidence of a
cavitary lesion in the lung. The proposed criteria
for diagnosis of chronic pulmonary aspergillosis
are shown in Table 3.
Patients with CNPA respond to systemic anti-
fungal therapy, but this may be a life-long
requirement. Itraconazole has been used as a
maintenance drug, and its slight inhibition of
immune response is deemed to be useful for
recovery from chronic pulmonary aspergillosis.
Interferon gamma was also helpful in Denning’s
series. Surgery should be reserved for patients
with reasonable respiratory reserve and no other
treatment options. It may be appropriate for
patients with severe haemoptysis if embolisation
fails. Aspergillus empyema is a complication of
aspergilloma and CNPA, or of the surgery under-
gone during treatment of these diseases, and is
slow to respond to treatment [13].
INVASIVE ASPERGILLOSIS
IA is the most severe presentation of aspergillosis.
The lung is usually the portal of entry, from
which the pathogen may disseminate to almost
any organ [5,17], the brain and skin being the next
most common targets.
Invasive pulmonary aspergillosis (IPA)
The lung is affected in up to 92% of cases of IA.
Pulmonary symptoms predominate, including
non-productive cough, pleuritic pain, low-grade
fever, haemoptysis and dyspnoea. Occasionally,
patients present with neurological manifestations
indicating dissemination and CNS involvement
[18].
Haemoptysis and pleuritic pain should be
considered alarming symptoms that may antici-
pate erosion of a major vessel and fatal bleeding.
In such cases, an emergency CT-scan should be
performed and, if the problem is conﬁrmed,
aggressive surgery is indicated [19].
Prompt recognition of this fungal infection is
essential for a successful outcome with intensive
antifungal therapy. However, both clinical
Table 3. Proposed enrolment criteria for prospective clinical studies of chronic pulmonary aspergillosis (CPA)
1. Chronic pulmonary or systemic symptoms (duration ¼ 3 months) compatible
with CPA, including at least one of the following symptoms: weight loss, productive
cough, or haemoptysis
2. Cavitary pulmonary lesion with evidence of paracavitary inﬁltrates, new cavity
formation, or expansion of cavity size over time
3. Either positive result of serum Aspergillus precipitin test or isolation of Aspergillus spp.
from pulmonary or pleural cavity
4. Elevated levels of inﬂammatory markers (C-reactive protein, plasma viscosity, or
erythrocyte sedimentation rate)
5. Exclusion of other pulmonary pathogens, by results of appropriate cultures and
serological tests, that are associated with similar disease presentation, including
mycobacteria and endemic fungi (especially Coccidioides immitis and Histoplasma
capsulatum)
6. No overt immunocompromising conditions (e.g., HIV infection, leukaemia, and
chronic granulomatous disease)
All criteria must be met for an individual to be enrolled; for criterion 3, one of the conditions must be met.
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symptoms and radiological manifestations may
be non-speciﬁc at early stages of the disease.
CT-scans are preferable to conventional chest
X-ray (Fig. 1). Radiological evidence of IPA
includes nodular lesions, with or without cavita-
tion, pleural-based, wedge-shaped inﬁltrates,
alveolar inﬁltrates and even interstitial and
ground-glass opacities [20]. Pleural effusion and
pneumothorax may be found.
The diagnosis of IPA is discussed further
below, and antifungal therapy is examined by
other authors in this supplement. Surgery may be
proposed for acute IPA in two situations: to
prevent catastrophic haemoptysis due to a para-
vascular lesion, or for resection of sequestered
mycotic deposits that could lead to generalised
re-infection [21].
Tracheobronchitis
Aspergillus tracheobronchitis is an uncommon
clinical form of IA, with fungal infection limited
entirely or predominantly to the tracheobronchial
tree. It has been described mainly in lung and
heart–lung transplant recipients [22–24], although
it may occur in other patients [25–29].
The clinical presentation includes coughing,
fever, wheezing, hypoxia, haemoptysis, and
sometimes dyspnoea and severe respiratory fail-
ure. Diagnosis is established by ﬁbreoptic bronch-
oscopy, with fungal growth sometimes
obstructing the main bronchus or nodular pla-
ques or pseudomembranes in the trachea or
bronchi. Biopsy indicates tissue necrosis and the
presence of hyphal elements. Therapy requires
systemic administration of antifungal agents or
aerosols if dissemination is excluded.
Sinusitis
Aspergillus may invade or colonise the paranasal
sinuses. Invasive Aspergillus sinusitis may behave
as aggressively as that caused by zygomycetes. It
has been described mainly in patients with
haematological malignancies [30–32] or in trans-
plant recipients [33], but cases in normal hosts
have also been described [34].
The symptoms of sinusitis include persistent
and signiﬁcant pain followed by progressive
ophthalmic signs, fever, discharge, cough, epis-
taxis, headache and, eventually, periorbital
involvement (Fig. 2). It may, or may not, accom-
pany lung aspergillosis. In the presence of the
aforementioned symptoms, CT or magnetic res-
onance imaging (MRI) and biopsy of any sinona-
sal lesion in a high-risk patient is mandatory.
Clinical features of orbital involvement or CT
manifestations of extrasinus spread should signal
the possibility of invasion [10,35]. The disease
may extend to the palate, contiguous sinuses,
orbit or brain.
CT-scans and MRI are the preferred radiologi-
cal techniques [36]. Pan-fungal and fungus-speci-
ﬁc PCR assays can be used in nasal lavages to
help establish the diagnosis [37]. Endoscopy may
also be useful for diagnosis and drainage [38].
Samples should be cultured in multiple media
(Sabouraud dextrose agar, potato dextrose agar,
and broth media). Negative specimen microscopy
is common [39]. Commercially available antibod-
ies may be useful in differentiating between
Aspergillus and zygomycetes in histological slides
[40].
The combination of systemic antifungal agents
and endoscopic surgery, associated or not with
Caldwell–Luc surgery, is the best therapeutic
option in aggressive cases of sinusitis [41]. Long-
term antifungal agents are recommended [42].
Mortality rates range from 11% to 80% and are
mainly related to intracranial invasion [30,34,43].
Cerebral aspergillosis
Cerebral aspergillosis may appear as an isolated
lesion or, more commonly, as part of a dissemin-
ated disease after haematogenous spread from
Fig. 2. Aspergillus sinusitis in a patient with refractory
chronic lymphocytic leukaemia receiving ﬂudarabine.
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pulmonary aspergillosis. Neutropenia, transplan-
tation and other forms of impaired cellular
immunity are the classic underlying conditions
[44,45]. Disseminated infection with CNS involve-
ment occurred in 17% of cases of IA in solid-
organ transplantation (SOT) studied in Spain.
Brain abscesses are relatively uncommon (0.6%)
in SOT patients, although Aspergillus is respon-
sible for 78% [46] and 58% [47] of biopsied
cerebral mass lesions in patients undergoing
allogeneic stem-cell transplant.
Cases of cerebral aspergillosis in non-immuno-
compromised patients after near drowning, preg-
nancy or surgery have been described [48–52].
As with other forms of IA, the clinical mani-
festations of cerebral aspergillosis parallel the
vascular tropism of the fungus, leading to infec-
tious cerebral vasculitis, mainly involving thal-
amoperforating and lenticulostriate arteries, with
a high frequency of thalamic or basal nuclei
lesions [53]. Presentation includes fever, seizures,
alteration of mental status, and CNS depression,
and may even be stroke-like. CNS Aspergillus
infections present either as mass lesions (e.g.,
brain abscess), or as cerebral infarcts, but rarely as
meningitis.
Differential diagnosis includes tuberculosis,
lymphoma, and toxoplasmosis. Radiological signs
are non-speciﬁc [54], and in the case of primary
lesions or in patients without a clear diagnosis,
stereotactic biopsy may be necessary. The cere-
brospinal ﬂuid is almost always sterile, but
detection of Aspergillus galactomannan in cere-
brospinal ﬂuid may contribute to the diagnosis
[55]. More usually, CNS aspergillosis is associated
with extraneural infection, allowing for sampling
without performance of a brain biopsy.
Brain aspergillosis has the worst prognosis
among all types of IA. The mortality risk usually
exceeds 90%. Data from case reports and a recent
retrospective study suggest that neurosurgical
interventions, e.g., abscess resections, stereotactic
drainage, and intraventricular catheters, might
improve the outcome in CNS aspergillosis. Vor-
iconazole, due to good penetration into the CNS
and brain tissue, has shown promising results in
the treatment of this infection. In a recent retro-
spective study, a complete or partial response
occurred in 35% of patients who were treated
with voriconazole for CNS aspergillosis, and the
survival rate was 31%. These data support the use
of voriconazole in this clinical setting [56,57].
Intracavitary administration of amphotericin B
has been used in this context, although its efﬁcacy
is controversial [58].
Cutaneous aspergillosis
Cutaneous aspergillosis may occur as a primary
event [59–62] or after haematogenous dissemin-
ation. Primary cutaneous aspergillosis has been
associated with many factors, including occlusive
dressings [63], neonatal status [64], leukaemia
[65], transplantation [66] or use of permanent
intravenous catheters [59]. Surgical wounds [67]
or burns [68] may also be invaded (Fig. 3).
In a recent series of patients with haematolog-
ical malignancies, 15 cases of cutaneous aspergil-
losis were reported. The skin was involved in 4%
of patients with leukaemia and documented
Aspergillus infection. Primary cutaneous aspergil-
losis was diagnosed in ﬁve cases. Infection was
fatal in 11 of 15 cases [69].
Clinically, cutaneous aspergillosis may appear
as asymptomatic nodules or as extensive and
necrotic lesions. Biopsy, which may prove to be a
rapid method of establishing diagnosis, should be
performed in all immunocompromised patients
with skin lesions.
Other forms of focal aspergillosis
An increasing number of reports deal with
unusual manifestations of invasive extrapulmo-
nary aspergillosis, sometimes in immunocompetent
Fig. 3. Wound aspergillosis in a liver transplant recipient.
Despite repeated debridements, new areas of necrosis
appeared soon afterwards.
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individuals. Examples include vertebral osteomy-
elitis, cholangitis, prosthetic vascular graft infec-
tion, endophthalmitis, pacemaker infection and
infective endocarditis. Early recognition of these
entities allows prompt initiation of antifungal
therapies and adjunctive surgical management, if
necessary, which may improve the prognosis
[4,70–72].
Aspergillus accounted for 26% of cases of
infective endocarditis occurring within a month
of transplantation [73]. It may affect native or
prosthetic valves and has been described after
valvular surgery, after drug abuse and in patients
requiring ventricular assistance devices [74–78].
Diagnosis is extremely difﬁcult, since blood cul-
tures usually remain negative [79–82]. The clinical
features include fever (74%), embolic episodes
(69%), a new or changing heart murmur (41%)
and sudden visual loss (13%) [83]. Patients with
mural endocarditis were more often immunosup-
pressed, especially due to SOTs, but had a lower
frequency of heart murmurs and embolic epi-
sodes. Echocardiography revealed vegetations in
78% of the cases in which it was performed.
Occasionally, diagnosis is established by cultur-
ing major arterial embolisms [84]. Mycotic aneur-
ysm, invasion of the wall of major arteries and
even intestinal infarction may occur [76]. The
mortality rate is high and surgery is usually
required.
Aspergillus osteomyelitis occurs mainly in
immunosuppressed hosts, although wound and
other infections in ‘normal’ hosts are seen. It can
be induced haematogenously, contiguously or by
direct inoculation. In children, contiguous spread
from an adjacent pulmonary infection is most
common, whereas in adults, haematogenous
spread is the rule [85–91]. Cases have been
described in patients with chronic granulomatous
disease or intravenous drug users [92–94]. The
spine is most frequently affected, and the clinical
presentation is non-speciﬁc. Back pain (53.6% of
cases) is the predominant symptom, while neu-
rological deﬁcits are present in 29.2% of patients.
White blood cell counts are elevated in 12.2% of
patients, and erythrocyte sedimentation rates are
>40 mm ⁄h in 39%. The overall recovery rate is
68.3%, and the mortality rate is 26.8% [88].
Radiology, CT-scan and MRI can help to establish
the diagnosis, determine the extent of the disease
and guide the biopsy. Diagnosis requires demon-
stration of characteristic hyphae in biopsy mater-
ial and culture of Aspergillus. Although Aspergillus
osteomyelitis is primarily treated medically, cases
with involvement of vital organs and those
involving neurological impairment or intolerable
pain due to irreversible joint damage may require
surgery [95]. Occasionally, vertebral osteomyelitis
is complicated by extradural abscess [85].
Disseminated aspergillosis
Disseminated aspergillosis is deﬁned as the
involvement of at least two non-contiguous organ
sites. Aspergillus may disseminate from the lungs
to almost any organ [5]. Overall, disseminated
disease has been described in 9–36% of kidney
recipients, 15–20% of lung recipients, 20–35% of
heart recipients and 50–60% of liver recipients
with IA [96]. Cytotoxic chemotherapy within a
month of death is a risk factor associated with
dissemination [97]. As mentioned, skin lesions
may be the ﬁrst clinical manifestation and may
lead to the diagnosis [98]. Uncommon manifesta-
tions of disseminated aspergillosis include end-
ophthalmitis [99], empyema, arthritis [100],
intestinal infarction [101] and thyrotoxicosis [102].
The clinical signiﬁcance of Aspergillus fungae-
mia in the setting of deep-seated aspergillosis has
not been clearly established. Among 107 microbi-
ologically documented Aspergillus infections in
patients with haematological diseases, Aspergillus
fungaemia was documented in nine of 89 (10.1%)
patients with pulmonary aspergillosis at a median
of 5 days from the onset of clinical signs of
infection and in one patient with central venous
catheter focal infection. The diagnostic role of
Aspergillus fungaemia in the setting of a deep-
seated infection is limited, because blood cultures
become positive when a microbiological or clin-
ical diagnosis of aspergillosis has already been
made. Aspergillus fungaemia does not seem to be
necessarily correlated with a disseminated infec-
tion or a poorer prognosis [103].
DIAGNOSIS OF INVASIVE
ASPERGILLOSIS
The diagnosis of IA remains a signiﬁcant chal-
lenge and is usually based on a combination of
compatible clinical ﬁndings in a patient with risk
factors and isolation of the microorganism, radio-
logical data, serological detection of antibodies
or antigens or histopathological evidence of
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invasion. Early and accurate diagnosis of IA is
essential in order to start timely antifungal ther-
apy and has an impact on the prognosis, but
unfortunately, the disease is non-speciﬁc in the
early stages.
The presence of clinical signs and symptoms
in a patient with recognised underlying condi-
tions, together with the presence of a positive
culture of one or more clinical samples for
Aspergillus, is a cause for concern. However,
fungus appears in clinical samples at late stages
of the disease, and a positive culture for Asperg-
illus does not always indicate true infection, as is
shown below. Finally, cases of IA without
positive cultures would go undiagnosed. For
these three reasons, other diagnostic tools are
necessary. Unfortunately, none of the available
diagnostic techniques are sufﬁciently speciﬁc
and sensitive to be reliable [17].
CLINICAL DIAGNOSIS
Imaging techniques and microbiological examina-
tion should come into play in the case of a patient
with underlying disease that is recognised as
contributing to the development of IA, in con-
junction with compatible signs and symptoms.
Imaging techniques
Chest radiographic ﬁndings in patients with
pulmonary Aspergillus infection include nodular
opacities, interstitial inﬁltrates, cavitary lung dis-
ease or a pulmonary embolus-type pattern; the
chest X-ray may be normal initially in up to 10%
of cases [104–107].
CT scanning is probably the most useful imag-
ing technique for the diagnosis of IA, since it may
reveal lung lesions up to 5 days earlier than
would radiographic techniques simply. A charac-
teristic ﬁnding is the ‘halo’ sign, which appears in
33–66% of patients with IA. However, it is short-
lived, and approximately 75% of the initial ‘halo’
signs disappear within a week [108]. Therefore, to
be useful for diagnosis, the CT-scan should be
performed within 5 days of the onset of the
disease. This lesion is not absolutely speciﬁc for
IA: in SOT recipients, a pulmonary halo sign is
less likely to correlate with IA, and may occur
with other types of pneumonia [109].
Another manifestation revealed by imaging,
the ‘air crescent’ sign, does not appear until the
third week of the disease, which is too late for it to
be useful for diagnosis [108].
Considering that, in the immunosuppressed
population, mould infections affect mainly the
lungs and sinuses, diagnostic approaches should
concentrate on these two anatomical locations,
with early and repeated CT-scans, if necessary. In
patients with brain lesions, the use of CT-scans or
MRI of the neuroaxis is essential for assessing the
presence and nature of infectious processes.
MICROBIOLOGICAL DIAGNOSIS
Currently available laboratory diagnostic meth-
ods include three groups of techniques: (i) histo-
pathological investigation for evidence of
invasion; (ii) isolation of the microorganism and
direct microscopy from clinical samples; and (iii)
non-invasive procedures, i.e., serological detec-
tion of antigens or nucleic material of Aspergillus,
or detection of antibodies.
Histopathological evidence of invasion
The histological diagnosis of IA requires the
presence of invasion by fungus of the Aspergillus
species. Aspergillus hyphae are 2–4 mm wide,
frequently septate and branch at 45. They are
best visualised on silver stains and may be
missed with routine haematoxylin–eosin stains.
In rapidly progressive infections, the hyphae are
of even diameter, whereas in more chronic cases,
they may have bulbous, widened areas [110].
Sporulation is rarely observed in tissue, except in
areas exposed to air (e.g., bronchi and cavitary
lesions). In the absence of sporulation, hyphae
cannot be readily distinguished from a large
number of pathogenic moulds, and the myco-
logical differential diagnosis includes Scedospori-
um, Fusarium, Scopulariopsis and many other rarer
moulds. Therefore, deﬁnitive diagnosis requires
a culture of the specimen positive for Aspergillus
[17].
The condition of many susceptible patients
prevents conﬁrmatory biopsy specimens from
being obtained. Furthermore, open lung biopsies
have only a 50% yield, probably because of
sampling error. Consequently, in practice, man-
agement should progress with the accumulation
of clinical, radiological and microbiological cri-
teria that provide different levels of certainty
[107]. Any suspicious lesion, e.g., skeletal or
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cutaneous, should be biopsied and cultured for
fungi.
Isolation of the microorganism and direct
microscopy from clinical samples
The early diagnosis of IA in SOT recipients is
difﬁcult because fungal cultures in these patients
may be negative even when infection is widely
disseminated. For instance, blood cultures are
notoriously insensitive in Aspergillus infections,
even with endocarditis. Bronchoalveolar lavage
ﬂuid, bronchial or endotracheal aspirates, pleural
ﬂuid, sputum, other respiratory ﬂuids and biopsy
specimens can be cultured in the laboratory [17].
Pathogenic species of Aspergillus recovered from
clinical samples usually grow easily and quickly
on routine bacteriological and mycological media.
Identiﬁcation is relatively straightforward,
according to microscopic criteria and colony
(conidial) colour. Formal identiﬁcation may
require culture on specialised media, e.g., Cza-
pek–Dox and malt extract. In the future, molecu-
lar methods will be used increasingly to identify
unusual species.
Aspergillus fumigatus has been considered the
most common species causing invasive aspergil-
losis, but several reports point to Aspergillus
terreus as an emerging agent of IA [111–114].
Most positive Aspergillus terreus cultures are
recovered from the lung, with a smaller propor-
tion being recovered from bone, sinuses or skin
[112].
It is increasingly admitted that cultures positive
for Aspergillus fumigatus, in the appropriate epi-
demiological and clinical setting, e.g., highly
immunosuppressed transplant patients, should
not be disregarded, as they are strongly associ-
ated with the presence or the risk of IA [115–117].
In the case of haematological patients, the isola-
tion of Aspergillus fumigatus by the microbiology
laboratory, even from non-sterile samples, is
generally regarded as potentially signiﬁcant. In
the case of heart transplant recipients in whom
infection is suspected, a culture positive for
Aspergillus has a positive predictive value (PPV)
of 60–70%; the PPV is 78–91% when Aspergillus
fumigatus is recovered, and 88–100% when
Aspergillus fumigatus is recovered from a respirat-
ory specimen other than sputum [118].
Unfortunately, this concept is being extrapola-
ted to other populations, thus increasing the
workload of the microbiology laboratory and
leading to an overestimation of the potential
clinical signiﬁcance of Aspergillus fumigatus iso-
lates [115]. If no other variables are considered,
the PPV is very low, and most of the isolates of
Aspergillus fumigatus do not indicate proven or
probable infection [119].
We recently studied theworkload created by the
isolation of Aspergillus fumigatus and its overall
clinical signiﬁcance in the microbiology laboratory
of a large general teaching hospital [6]. Aspergillus
fumigatus represented 5.6% of all fungal isolates in
the laboratory. It was isolated 21 times per 10 000
hospital admissions, but only four of 10 000
isolates were from patients with IA. The overall
probability that a culture positive for Aspergillus
fumigatus indicated a case of IA in an unselected
hospital populationwas 22.3%. The PPVwas 60%,
but below 15% in other populations. This study
provides a useful score for predicting the probab-
ility that an isolate of Aspergillus fumigatus indi-
cates IA, which may be of particular interest in
cases without histological conﬁrmation. The score
gives different numbers of points to the types and
numbers of samples, and to the presence of
leukaemia, corticosteroid therapy or neutropenia.
Another attempt to discriminate between inva-
sive and coloniser strains resulted in the study of
the pathogenicity of a speciﬁc isolate. We found a
good correlation between the elastase activity
index and the invasiveness of clinical isolates of
Aspergillus fumigatus. Higher elastase activity
indexes were related to IA, whereas if the elastase
activity index was <1, the probability of invasive
disease was very low [120].
Regarding susceptibility testing of fungal iso-
lates, the correlation between MIC and clinical
response of increased MICs for moulds has not
been established using the standardised method
for mould susceptibility (CLSI, formerly NCCLS,
protocol M-38A). However, given the emerging
development of resistance, susceptibility testing
for available antifungal drugs is warranted in the
case of infections caused by Aspergillus and other
moulds.
Non-invasive procedures
Serological detection of antigens
As mentioned, traditional microbiological meth-
ods (culture of clinical samples and direct micr-
oscopy) have low sensitivity, do not help to
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discriminate between infection and colonisation,
and may only give positive results at late stages of
the disease. Furthermore, in some cases, the under-
lying condition of the patient prevents the use of
invasive techniques to obtain suitable clinical
samples. For these reasons, methods for the detec-
tion of different circulating markers (e.g., fungal
cell wall components and genomic fungal DNA)
have been developed in recent years [119,121,122].
The use of serological tests of blood or other ﬂuids
(e.g., serum, urine and bronchoalveolar lavage
ﬂuid) in the diagnosis of IA is the focus of ongoing
clinical investigations [117,123–125].
Several molecules could be used as markers of
infection, but two of them are of special interest:
Aspergillus galactomannan (GM) and (1 ﬁ 3)-b-
glucan (BG).
GM was the ﬁrst antigen detected in experi-
mentally infected animals and in patients with IA
[126–128]. It is an exo-antigen released from
Aspergillus hyphae while they invade host tissue
and can be detected in serum and other body
ﬂuids by an ELISA-based immunocapture assay.
This test may help provide an early diagnosis of
IA (median of 6 days before signs and symptoms
of the disease become apparent) before the infec-
tion becomes too extended. The Platelia (Sanoﬁ
Diagnostic Pasteur) sandwich ELISA for the
detection of GM is currently one of the methods
under study. It has a high speciﬁcity (above 85%)
and a reported sensitivity that varies widely
(between 30% and 100%) [122,125,129,130]. A
potential explanation for this variation in sensi-
tivity may be the different cut-off values for a
positive GM result in Europe and the USA
(1.5 ng ⁄mL and 0.5 ng ⁄mL, respectively). The
cut-off value is under revision, and several stud-
ies have re-evaluated it. Maertens et al. showed, in
adult neutropenic cancer patients, that the analy-
sis of a single clinical sample using a cut-off of 0.8
was equivalent to obtaining two consecutive
positive samples using a cut-off of 0.5 (‘dynamic’
cut-off) [131]. The sensitivity, speciﬁcity, PPV and
negative predictive value (NPV) obtained in this
study are shown in Table 4. In our opinion, the
use of this ‘dynamic’ cut-off will probably pro-
vide the best results in terms of diagnostic
effectiveness, or will exclude the possibility of IA.
The false-positive results with GM are a major
drawback of this test, and their nature remains
difﬁcult to determine. Some drugs, e.g., cyclo-
phosphamide [132] and piperazillin–tazobactam
[133], are potential inducers, and certain foods
have been proposed as a source of components
that lead to false-positive results [134].
BG is one of the main cell-wall polysaccharide
components of Aspergillus [135]; it can be colouri-
metrically detected and is useful in diagnosis.
This component is speciﬁc for fungi except for
zygomycetes and cryptococci [136]. It is detect-
able in blood during invasive fungal infections
(IFI) caused by Aspergillus, Fusarium and Acremo-
nium [137]. The recently marketed Glucatell assay
(Associates of Cape Cod, Falmouth, MA, USA)
involves the colourimetric detection of BG in
clinical samples. The current cut-off for consider-
ing an assay to be positive is a level of BG
‡120 pg ⁄mL in at least one serum sample [138].
The sensitivity of the test ranges from 50% to
87.5% [119,121,138,139].
One of the problems with BG detection is the
presence of false-positive results that decrease the
speciﬁcity of the test. Haemodialysis with cellu-
lose membranes is a well-known explanation for
false-positive results with BG, but other reasons
remain unexplained [138,140].
Some authors have proposed that a reasonable
approach to the clinical application of these
assays would be serial screening (weekly or
bi-weekly) of patients at high risk of IFI. A recent
study published by Pazos et al. compared Platelia
and Glucatell in adult haematological malignancy
patients who were prospectively analysed twice-
weekly. The sensitivity, speciﬁcity, PPVs and
NPVs are shown in Table 5. The results of this
comparison are interesting: both tests were pos-
itive in the same patients with IA, and the kinetics
of both markers were very similar. BG tended to
become positive earlier than GM. The authors
found discrepancies in patients with false-positive
Table 4. Sensitivity, speciﬁcity, positive predictive value
(PPV) and negative predictive value (NPV) of different cut-
offs with Platelia in a population of adult neutropenic
cancer patients (131)
One single
positive sample
(cut-off 0.8)
Two correlative
samples
(cut-off 0.5)
Sensitivity 96.5 96.5
Speciﬁcity 97.3 98.6
PPV 93.3 98.6
NPV 98.6 98.4
Clinical efﬁcacy 97 98
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results: one of the two tests was negative in these
patients. The combined analysis of both markers
was important to identify the patients with false-
positive results, since IA could be conﬁrmed only
when both markers were positive. One possible
solution to the problem of false-positive results
from each test would be conﬁrmation by other
tests.
The diagnosis of IA is the most important
feature of the serological detection of GM and BG,
as the detection of antigenaemia dictates the start
of therapy [130]. Another advantage is that the
detection of these markers may correlate the
concentration in serum with treatment efﬁcacy.
It has been demonstrated that, for GM, the levels
decline when the patient is responding to anti-
fungal treatment and rise with treatment failure
[141,142]. Furthermore, monitoring of BG in
serum has recently been shown to be a useful
tool for predicting the therapeutic outcome of
patients with IA [138].
Detection of nuclear material of Aspergillus
A speciﬁc Aspergillus PCR assay has also been
studied in the diagnosis of IA. Some studies have
shown very good results, with a sensitivity and
speciﬁcity of 100% and 89%, respectively [143].
Lung specimens show much higher sensitivity
values than blood specimens [144].
Recent protocols call for universal fungal PCR
primers, which enable the detection of a broad
range of fungi [145–147] with a sensitivity of 1–
10 fg of fungal DNA. In one study, the sensitivity
of the PCR with whole blood was 100% in
patients with documented IFI when two or more
samples were analysed [146].
Quantitative PCR can contribute to monitoring
of the fungal burden in response to treatment, as
has been shown for PCR monitoring of cyto-
megalovirus disease [148]. The quantitative PCR
for diagnosis of IA with bronchoalveolar lavage
ﬂuid has shown sensitivity and speciﬁcity values
of 67% and 100%, respectively [145]. In this
study, the authors conclude that the detection of
GM in bronchoalveolar lavage ﬂuid and a
quantitative PCR assay may enhance broncho-
scopic identiﬁcation of Aspergillus species as
being the cause of pulmonary disease in haema-
topoietic stem-cell transplant recipients, and may
facilitate diagnoses based on bronchoscopy in
high-risk patients.
The previous studies reported that PCR has
reasonable sensitivity (ranging from 50% to
100%) and speciﬁcity when used to test samples
from patients at high risk of IA, but the clinical
value of these assays remains unclear, despite the
fact that Skladny et al. demonstrated a high
correlation between positive histology, culture or
chest CT ﬁndings and nested-PCR results [143].
Another recent study reported the sensitivity of
PCR as being lower (63.5%) [149]. The authors
attribute this low sensitivity to the small number
of episodes of IA; however, in our opinion, it
might be the actual situation in most institutions
that care for patients susceptible to Aspergillus
infections.
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